NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BAFNAPH · data 2026-10-30
Bafna Pharmaceuticals Limited
In plain words
Price: 6.7% below its 52-week high of ₹479.95.
Delivery: 79.1% of traded shares were kept for delivery over the last 10 sessions, against 76.5% over the last 47.
Latest results: a net profit of ₹0 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹143 cr |
| Net profit (last 12 months) | ₹8 cr |
| Sales growth, 3 years (yearly) | 9.3% |
| Profit growth, 3 years (yearly) | -0.7% |
Latest results in brief (Q4 FY26)
BAFNAPH Q4 FY26 results (standalone figures, as filed on NSE).
Revenue was ₹42.24 crore.
Net profit was ₹2.75 crore.
Operating margin was 8.4%.
EPS was ₹1.16.
BAFNAPH के Q4 FY26 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹42.24 करोड़।
शुद्ध मुनाफ़ा: ₹2.75 करोड़।
ऑपरेटिंग मार्जिन: 8.4%।
EPS: ₹1.16।
BAFNAPHના Q4 FY26 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹42.24 કરોડ.
ચોખ્ખો નફો: ₹2.75 કરોડ.
ઓપરેટિંગ માર્જિન: 8.4%.
EPS: ₹1.16.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 26 May 25Results Q4 FY25 results: net profit ₹1.3 cr +1.5% next session
- 7 Feb 25Results Q3 FY25 results: net profit ₹0.9 cr -1.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹27 cr | ₹0 cr | — | 3.3% | 0.03 |
| Mar 2026 | ₹42 cr | ₹3 cr | — | 8.4% | 1.16 |
| Dec 2025 | ₹38 cr | ₹2 cr | +93.7% | 8.0% | 0.78 |
| Dec 2024 | ₹33 cr | ₹1 cr | — | 9.2% | 0.4 |
Shareholding trend
| Holder | Jun 2026 | Dec 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 88.30% |
| Foreign institutions (FII) | 9.34% | 9.34% | 8.53% | 0.00% |
| Domestic institutions (DII) | — | — | 0.00% | 0.00% |
| Mutual funds | — | — | 0.00% | 0.00% |
| Retail investors | 4.98% | 4.48% | 5.11% | 4.86% |
| Number of shareholders | 7,062 | 7,119 | 7,142 | 7,214 |
Common questions
What was Bafna Pharmaceuticals Limited's latest quarterly profit?
Bafna Pharmaceuticals Limited reported a net profit of ₹0 cr for the quarter ended Jun 2026, on revenue of ₹27 cr.
How much do promoters hold in Bafna Pharmaceuticals Limited?
Promoters held 75.00% of Bafna Pharmaceuticals Limited at the end of Jun 2026, with 0.00% of promoter shares pledged.
Is Bafna Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.39.
What is Bafna Pharmaceuticals Limited's P/E ratio?
About 136.1, based on the last 12 months' earnings and a price of ₹447.9 (data 2026-10-30).
What is the 52-week high and low of Bafna Pharmaceuticals Limited?
The 52-week high is ₹479.95 and the 52-week low is ₹94.77.
Similar companies
Kopran Limited (KOPRAN) · Bajaj Healthcare Ltd (BAJAJHCARE) · Remus Pharmaceuticals Ltd. (REMUS) · Lincoln Pharmaceuticals Ltd (LINCOLN) · Sigachi Industries Limited (SIGACHI)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BAFNAPH in NSE Scanner →